Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25408699 | 0.84 | — | — | |
| SCHEMBL1060663 | 0.81 | TSHR (0.30) | TSHR | |
| SCHEMBL8741525 | 0.77 | — | — | |
| SCHEMBL23783512 | 0.77 | — | — | |
| SCHEMBL1059438 | 0.77 | — | — | |
| SCHEMBL4881254 | 0.74 | MAOB (0.34) | TSHR | |
| SCHEMBL10632508 | 0.72 | — | — | |
| SCHEMBL2384813 | 0.71 | TSHR (0.39) | TSHR | |
| SCHEMBL314815 | 0.71 | — | — | |
| SCHEMBL5057324 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394944-B2 | for detection and quantitation of single nucleotide polymorphisms (SNPs) using polymerase chain reaction (PCR); kits | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8063196-B2 | Highly orthogonal universal sequences for use in nucleic acid assays | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-7993838-B2 | Nucleic acid primers and probes for detecting human and avian influenza viruses | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100330548-A1 | Nucleic Acid Primers and Probes for Detecting Human and Avian Influenza Viruses | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2021516-B1 | NUCLEIC ACID PRIMERS AND PROBES FOR DETECTING HUMAN AND AVIAN INFLUENZA VIRUSES | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-1785491-B1 | Dual-purpose primers and probes for providing enhanced hybridization assays by disruption of secondary structure formation | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20100121056-A1 | PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR | HUMAN GENETIC SIGNATURES PTY. LTD. (AU) | 2010-05-13 | — | — | US | disclosed |
| US-20100047778-A1 | Methylation Specific Primer Extension Assay for the Detection of Genomic Imprinting Disorders | SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (US) | 2010-02-25 | — | — | US | disclosed |
| EP-2021516-A4 | NUCLEIC ACID PRIMERS AND PROBES FOR DETECTING HUMAN AND AVIAN INFLUENZA VIRUSES | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2009-05-20 | — | — | EP | disclosed |
| US-20090075273-A1 | Planar Waveguide Detection Chips and Chambers for Performing Multiple PCR Assays | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-5430136-A | Oligonucleotides having selectably cleavable and/or abasic sites | CHIRON CORPORATION (US) | 1995-07-04 | — | — | US | disclosed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| US-5367066-A | Oligonucleotides with selectably cleavable and/or abasic sites | CHIRON CORPORATION (US) | 1994-11-22 | — | — | US | disclosed |
| US-5332845-A | In DNA synthesis | CHIRON CORPORATION (US) | 1994-07-26 | — | — | US | disclosed |
| EP-0543889-A4 | INCORPORATION OF SELECTABLY CLEVABLE AND/OR ABASIC SITES INTO OLIGONUCLEOTIDE CHAINS AND REAGENTS THEREFOR | CHIRON CORP (US) | 1994-05-18 | — | — | EP | disclosed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
| US-5258506-A | Photolabile reagents for incorporation into oligonucleotide chains | CHIRON CORPORATION (US) | 1993-11-02 | — | — | US | disclosed |
| US-5252760-A | Method of using colored phosphorylating reagents | CHIRON CORPORATION (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0543889-A1 | INCORPORATION OF SELECTABLY CLEVABLE AND/OR ABASIC SITES INTO OLIGONUCLEOTIDE CHAINS AND REAGENTS THEREFOR | CHIRON CORPORATION (US) | 1993-06-02 | — | — | EP | disclosed |
| EP-0304215-A2 | Phosphorylating reagents and method of using the same | CHIRON CORPORATION (US) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121056-A1 | PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR | POLRMT, POLN, RNASE1 | TSHR 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.